This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Helmholtz-Zentrum Dresden-Rossendorf - Institute of Radiopharmaceutical Cancer Research, Instituto Portugues De Oncologia Do Porto Fg, Epe, Universidade Nova De Lisboa. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 7 Years Active: 2022
Title: The Innovations of Wengang Chai
Introduction
Wengang Chai, an inventive mind based in Caparica, Portugal, has made a significant contribution to the field of cancer research through his unique patent. His innovative work focuses on the development of an antibody that targets tumor antigens, paving the way for enhanced detection and treatment options for human diseases, particularly cancer.
Latest Patents
Chai holds a patent for the invention entitled "L2A5 antibody or functional fragment thereof against tumour antigens." This groundbreaking invention provides an antibody, or functional antibody fragments, directed against a distinctive group of antigens identified in cancer. The patent outlines the nucleotide sequences derived from the L2A5 monoclonal antibody, which includes a variable heavy chain domain and a variable light chain domain with a specific amino acid sequence. This unique DNA/amino acid sequence conjugation has not been previously described and offers potential solutions for the detection, treatment, and prevention of human diseases, including various forms of cancer.
Career Highlights
Throughout his career, Wengang Chai has held notable positions at prestigious institutions, contributing to advancements in cancer research. He has worked at the Universidade Nova de Lisboa and the Instituto Português de Oncologia do Porto, where he has further honed his expertise and developed his innovative ideas into successful patents.
Collaborations
Chai's journey has been marked by collaborations with esteemed colleagues, including Paula Alexandra Quintela Videira and Carlos Manuel Mendes Novo. These partnerships have likely fueled Chai's research endeavors and contributed to the successful development of his innovative projects.
Conclusion
Wengang Chai's invention of the L2A5 antibody represents a significant step forward in cancer research and treatment. Through his dedication to innovation and collaboration with other experts in the field, Chai continues to impact the medical community positively. His work exemplifies the vital role of inventors in advancing healthcare solutions, demonstrating that innovation remains at the forefront of tackling critical challenges in human health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile